Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 146, Issue 1-2, Pages 171-175Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2003.10.046
Keywords
multiple sclerosis; matrix metalloprotease; tissue inhibitor of matrix metalloprotease; intravenous glucocorticosteroids; therapy
Categories
Ask authors/readers for more resources
Matrix metalloproteinases (MMPs) are believed to play a role in the pathogenesis of multiple sclerosis (MS). As methylprednisolone is the treatment of choice for a relapse, we investigated the effect of methylprednisolone on blood levels of MMPs. Baseline TIMP-1 and MMP-2 levels were lower in MS patients than in healthy controls. MMP-9 levels tended to be elevated. During therapy, MMP-9 levels demonstrate a dose-dependent increase. No effect was noted on TIMP-1 and MMP-2 levels. The short-lived increase of MMP-9 plasma levels may be at least in part due to an activation and an increase of granulocytes and monocytes by methylprednisolone. (C) 2003 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available